Metformin (dimethylbiguanide) is an orally administered drug used to lower blood glucose concentrations in patients with non-insulin-dependent diabetes mellitus (NIDDM).1 It improves insulin sensitivity and thus decreases the insulin resistance that is prevalent in NIDDM. The efficacy of glycemic control achieved with metformin is similar to that achieved with sulfonylureas, although their modes of action differ. Metformin can be used either as initial therapy or as an additional drug when sulfonylurea therapy alone is inadequate. In this article we shall discuss the pharmacology and clinical use of metformin, which is now available in the United States.The Burden of Non-Insulin-Dependent . . .
Resistance to the action of insulin can result from a variety of causes, including the formation of abnormal insulin or proinsulin molecules, the presence of circulating antagon...
The objective of this study is to understand the metabolic and immunologic basis of diabetes in adult blacks with diabetic ketoacidosis (DKA). Twenty-one black adults presenting...
Insulin-dependent diabetes mellitus (IDDM) is a chronic disorder that results from autoimmune destruction of the insulin-producing pancreatic beta cells. Much has been learned d...
Although a strong genetic susceptibility has been established for NIDDM and a maternal transmission of the disease predominates in some populations, a relationship between paren...
Tissue sensitive to insulin and insulin binding to monocytes were evaluated in 15 nonobese maturity-onset diabetics and in 16 healthy controls. Insulin sensitivity was determine...
Social media, news, blog, policy document mentions